Although pioglitazone did not meet the pre-specified significance level for the primary outcome, it was associated with highly significant reductions in the individual variables of steatosis, inflammation, and hepatocellular ballooning, as well as with improvements in insulin resistance and liver-enzyme levels.
← all excerpts
Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway.
1
—
—